| The great escape; the hallmarks of resistance to antiangiogenic therapy JR Van Beijnum, P Nowak-Sliwinska, EJM Huijbers, VL Thijssen, ... Pharmacological reviews 67 (2), 441-461, 2015 | 202 | 2015 |
| Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes ZR Huinen, EJM Huijbers, JR van Beijnum, P Nowak-Sliwinska, ... Nature Reviews Clinical Oncology 18 (8), 527-540, 2021 | 125 | 2021 |
| COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects DM Smadja, SJ Mentzer, M Fontenay, MA Laffan, M Ackermann, J Helms, ... Angiogenesis 24, 755-788, 2021 | 113 | 2021 |
| Role of the tumor stroma in resistance to anti-angiogenic therapy EJM Huijbers, JR van Beijnum, VL Thijssen, S Sabrkhany, ... Drug Resistance Updates 25, 26-37, 2016 | 83 | 2016 |
| CD44 enhances tumor aggressiveness by promoting tumor cell plasticity YWJ Paulis, EJM Huijbers, DWJ van der Schaft, PMMB Soetekouw, ... Oncotarget 6 (23), 19634, 2015 | 66 | 2015 |
| Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors MMG Kes, J Van den Bossche, AW Griffioen, EJM Huijbers Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1874 (2), 188427, 2020 | 55 | 2020 |
| Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer J Femel, EJM Huijbers, F Saupe, J Cedervall, L Zhang, P Roswall, ... Oncotarget 5 (23), 12418, 2014 | 50 | 2014 |
| Vaccination against the extra domain‐B of fibronectin as a novel tumor therapy EJM Huijbers, M Ringvall, J Femel, S Kalamajski, A Lukinius, M Åbrink, ... The FASEB Journal 24 (11), 4535-4544, 2010 | 50 | 2010 |
| Vaccination approach to anti-angiogenic treatment of cancer MQ Wentink, EJM Huijbers, TD de Gruijl, HMW Verheul, AK Olsson, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1855 (2), 155-171, 2015 | 36 | 2015 |
| Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis K van Loon, EJM Huijbers, AW Griffioen Cancer and Metastasis Reviews 40, 191-203, 2021 | 33 | 2021 |
| The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B—a prerequisite for clinical development EJM Huijbers, J Femel, K Andersson, H Björkelund, L Hellman, AK Olsson Vaccine 30 (2), 225-230, 2012 | 27 | 2012 |
| The tumor vasculature an attractive CAR T cell target in solid tumors P Akbari, EJM Huijbers, M Themeli, AW Griffioen, JR van Beijnum Angiogenesis 22, 473-475, 2019 | 24 | 2019 |
| Identification of potent biodegradable adjuvants that efficiently break self-tolerance—a key issue in the development of therapeutic vaccines M Ringvall, EJM Huijbers, P Ahooghalandari, L Alekseeva, T Andronova, ... Vaccine 28 (1), 48-52, 2009 | 23 | 2009 |
| Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disorders K van Loon, J Yemelyanenko-Lyalenko, C Margadant, AW Griffioen, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1873 (2), 188354, 2020 | 22 | 2020 |
| Targeting serglycin prevents metastasis in murine mammary carcinoma A Roy, J Femel, EJM Huijbers, D Spillmann, E Larsson, M Ringvall, ... PloS one 11 (5), e0156151, 2016 | 22 | 2016 |
| Targeting tumor vascular CD99 inhibits tumor growth EJM Huijbers, IM Van Der Werf, LD Faber, LD Sialino, P Van der Laan, ... Frontiers in Immunology 10, 651, 2019 | 20 | 2019 |
| Vaccines targeting self‐antigens: mechanisms and efficacy‐determining parameters F Saupe, EJM Huijbers, T Hein, J Femel, J Cedervall, AK Olsson, ... The FASEB Journal 29 (8), 3253-3262, 2015 | 20 | 2015 |
| Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment P Nowak-Sliwinska, JR van Beijnum, EJM Huijbers, PC Gasull, L Mans, ... British Journal of Cancer 120 (2), 218-228, 2019 | 16 | 2019 |
| Propofol extravasation in a breast cancer patient EJM Huijbers, JW Baars, PFE Schutte, JHM Schellens, JH Beijnen Journal of Oncology Pharmacy Practice 14 (4), 195-198, 2008 | 16 | 2008 |
| An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature EJM Huijbers, JR van Beijnum, CT Lê, S Langman, P Nowak-Sliwinska, ... Vaccine 36 (21), 3054-3060, 2018 | 15 | 2018 |
